REG1V logo

Revenio Group Oyj Stock Price

HLSE:REG1V Community·€372.5m Market Cap
  • 2 Narratives written by author
  • 0 Comments on narratives written by author
  • 17 Fair Values set on narratives written by author

REG1V Share Price Performance

€14.00
-13.80 (-49.64%)
€19.38
Fair Value
€14.00
-13.80 (-49.64%)
27.7% undervalued intrinsic discount
€19.38
Fair Value
Price €14.00
AnalystConsensusTarget €19.38
AnalystLowTarget €15.00

REG1V Community Narratives

·
Fair Value €19.38 27.7% undervalued intrinsic discount

Global Ophthalmic Diagnostics Will Expand Through AI Integration

0users have liked this narrative
0users have commented on this narrative
14users have followed this narrative
·
Fair Value €15 6.7% undervalued intrinsic discount

Ophthalmic Expansion And Visionix Integration Will Shape Balanced Long Term Prospects

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
€19.38
27.7% undervalued intrinsic discount
Revenue
9.5% p.a.
Profit Margin
22.49%
Future PE
20.09x
Price in 2029
€23.14
€15
6.7% undervalued intrinsic discount
Revenue
7.85% p.a.
Profit Margin
20.25%
Future PE
18.4x
Price in 2029
€18.22

Trending Discussion

Updated Narratives

REG1V logo

REG1V: Dividend Pause And Acquisition Integration Will Support Future Upside Repricing

Fair Value: €19.38 27.7% undervalued intrinsic discount
14 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
REG1V logo

Ophthalmic Expansion And Visionix Integration Will Shape Balanced Long Term Prospects

Fair Value: €15 6.7% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet established dividend payer.

0 Risks
3 Rewards

Revenio Group Oyj Key Details

€111.0m

Revenue

€33.4m

Cost of Revenue

€77.7m

Gross Profit

€62.0m

Other Expenses

€15.7m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 06, 2026
0.59
69.94%
14.15%
5.1%
View Full Analysis

About REG1V

Founded
2001
Employees
243
CEO
Jouni Toijala
WebsiteView website
www.reveniogroup.fi

Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Sensors that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used by veterinarians, ophthalmologists and other personnel to measure intraocular pressure in animal patients. It also provides imaging devices comprising iCare EIDON, a device with confocal retinal imaging; iCare DRSplus, a device for pupil imaging; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. In addition, the company offers iCare ILLUME, a screening software that helps to detect the early signs of diabetic retinopathy, age-related macular degeneration, and glaucoma using artificial intelligence; iCare CLINIC cloud software to store long-term IOP data; and Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities. Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.